IMMU Immunomedics, Inc. Company Research Saturday, January 11,

New Post Public Reply Private Reply Replies (0) Message Board
Rosner
IMMU Immunomedics, Inc. $IMMU Company Overview 

Stock Message Board http://investorshangout.com/search?q=IMMU&...mp;yt1=Go!

Last Updated: Saturday, January 11, 2014 11:28:20 PM

Immunomedics, Inc. IMMU Current Price and Quotes
Last Price 6.10
Previous Close 5.18 Open 5.94
Daily Range 6.11 - 5.55 52wk Range 7.35 - 2.11
Volume 8,748,267 Dividend N/A
Average Vol (3m) 1,286,117 Yield N/A
Immunomedics, Inc. IMMU
Company Information

300 American Road
Morris Plains, NJ 07950

Phone: (973) 605-8200

Immunomedics, Inc. IMMU
Not Available

Immunomedics, Inc. IMMU
Financial Reportings and Disclosures

Reporting Status U.S. Reporting: SEC Filer
Latest Report Sep 30, 2013 10-Q
CIK 0000722830
Fiscal Year End 6/30
OTC Marketplace Not Available
Profile Data

SIC - Industry Classification Not Available
Incorporated In: DE, USA
Year of Inc. Not Available
Employees Not Available
Service Providers

Auditor/Accountant
Not Available
Legal Counsel
Not Available
Investor Relations Firm
Not Available

Immunomedics, Inc. IMMU
IMMU Security Details

Share Structure

Market Value1 $507,119,108 a/o Jan 10, 2014
Shares Outstanding 83,134,280 a/o Nov 01, 2013
Float Not Available
Authorized Shares Not Available
Par Value  0.01
Shareholders

Shareholders of Record 619 a/o Aug 29, 2008
Security Notes

New Issue=10-83 1,000,000 shs in units (1 sh Com & 1 Warr 10-6-86) at $2.50 per unit (best efforts-all or none) by Creative Securities Corp.
Capital Change=6-85 shs increased by 2 for 1 split
Latest Addt'l Issue=1-92 2,000,000 shs at $14 by Allen & Co., Inc. et al.
Short Selling Data

Short Interest 9,100,964 (-1.15%)
Nov 30, 2010
Significant Failures to Deliver  No
Transfer Agent(s)

Broadridge Financial Solutions, Inc.

Immunomedics, Inc. IMMU Financials
Period Ending Jun 30, 2013 Jun 30, 2012 Jun 30, 2011 Jun 30, 2010
Total Revenue 4,962 32,734 14,709 60,930
Cost of Revenue 393 427 419 960
Gross Profit 4,569 32,307 14,290 59,970
Operating Expenses

Research and Development 29,165 24,824 25,369 19,854
Sales, General and Admin. 6,981 6,609 7,944 6,183
Non-Recurring Items - - - -
Other - - - -
Operating Income (31,576) 874 (19,023) 33,933
Income From Continuing Operations

Add'l Income/Expense Items 19,350 32 3,888 1,834
Earnings Before Interest and Tax (12,226) 906 (15,135) 35,767
Interest Expense - - - -
Earnings Before Tax (12,226) 906 (15,135) 35,767
Income Tax 44 210 110 (1,229)
Minority Interest (105) (114) (174) -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (12,165) 810 (15,070) 36,996
Non Recurring Events

Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (12,165) 810 (15,070) 36,996
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (12,165) 810 (15,070) 36,996

Immunomedics, Inc. IMMU Recent News

Jan 9, 2014 Immunomedics Announces Initiation of Phase III Clinical Trial of Clivatuzumab Tetraxetan in Patients With Pancreatic Cancer
Jan 9, 2014 The Zacks Analyst Blog Highlights: Can-Fite, Amgen, Cubist, Immunomedics and NPS Pharmaceuticals
Jan 6, 2014 Drug Designation, Conference Participations, Induction of Winners, Software Solution Deployment, and Patent Issuance - Research Report on GSK, Centene, WuXi PharmaTech, Allscripts, and Immunomedics
Dec 31, 2013 Immunomedics Announces U.S. Patent for Antibody-SN-38 Conjugates
Dec 25, 2013 FDA Drug Approvals, Newly Elected Board of Directors, and Stock Price Updates on Healthcare Companies - Research Report on Theravance, Quintiles, Ironwood, Progenics, and Immunomedics
Dec 19, 2013 Health Care Sector Technical Data: XOMA, Celldex Therapeutics, Illumina, and Immunomedics
Dec 17, 2013 New Leaders, Quarterly Dividends, Positive Clinical Results, and Data Presentations - Research Report on Quintiles, CR Bard, Theravance, Immunomedics and Progenics Pharmaceuticals
Dec 9, 2013 Immunomedics Reports Promising Activity With Veltuzumab in Relapsed Immune Thrombocytopenia
Dec 9, 2013 Stock Price Updates, Conferences Participations - Research Report on Quest Diagnostics, Pharmacyclics, Health Management Associates, Theravance, and Immunomedics
Dec 4, 2013 Immunomedics Announces Outcome of 2013 Annual Meeting of Stockholders

1
2
3
next >

IMMU Immunomedics, Inc. Research DD Guide

Stock Message Board http://investorshangout.com/search?q=IMMU&...mp;yt0=Go!
Stock Quote http://www.otcmarkets.com/stock/IMMU/quote
Stock Chart http://www.otcmarkets.com/stock/IMMU/chart
Company Info http://www.otcmarkets.com/stock/IMMU/company-info
Recent News http://www.otcmarkets.com/stock/IMMU/news
Financials http://www.otcmarkets.com/stock/IMMU/financials
Filings and Disclosure http://www.otcmarkets.com/stock/IMMU/filings
Short Sales http://www.otcmarkets.com/stock/IMMU/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/IMMU/insider-transactions
Research Reports http://www.otcmarkets.com/stock/IMMU/research
Summary http://finance.yahoo.com/q?s=IMMU
Historical Prices http://finance.yahoo.com/q/hp?s=IMMU+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=IMMU
Basic Chart http://finance.yahoo.com/q/bc?s=IMMU+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=IMMU+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=IMMU+Headlines
Press Releases http://finance.yahoo.com/q/p?s=IMMU+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=IMMU+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=IMMU+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=IMMU+Industry
Major Holders http://finance.yahoo.com/q/mh?s=IMMU+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=IMMU+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=IMMU+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=IMMU
Balance Sheet http://finance.yahoo.com/q/bs?s=IMMU
Cash Flow http://finance.yahoo.com/q/cf?s=IMMU+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/IMMU
Market Watch http://www.marketwatch.com/investing/stock/IMMU
Bloomberg http://www.bloomberg.com/quote/IMMU:US
Morningstar http://quotes.morningstar.com/stock/s?t=IMMU
Bussinessweek http://investing.businessweek.com/research/st...icker=IMMU
Barchart http://www.barchart.com/quotes/stocks/IMMU
OTC Short Report http://otcshortreport.com/index.php?index=IMMU
Investopedia http://www.investopedia.com/markets/stocks/IMMU/?wa=0
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 190

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 230

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 144

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 242

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
LexisNexis Debuts AI-Guided Field Clarity at IACP 2026

Updated Category News Views 59

LexisNexis Takes a Serious Step Forward The world of law enforcement reporting just got a shake-up. LexisNexis Coplogic Solutions launched a souped-up version of its Desk Officer Reporting System (DORS) at the IACP 2026 event. They paired DORS with Field Clarity, a newfangled AI-powered assistant that aims to make police reporting slicker and more accurate. You can bet...

Continue Reading
RYBREVANT's Promising Results in HNSCC Treatment

Updated Category News Views 80

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Continue Reading
Survivors Secure $800M Settlement with NY Archdiocese

Updated Category News Views 299

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 242

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event

Updated Category News Views 96

Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...

Continue Reading
Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 104

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading

Top 5 Most Recently Viewed Articles

Macao's 25-Year Journey: Celebrating Growth and Prosperity

Updated Category News Views 161

Macao's Remarkable Development Over 25 Years In a vibrant celebration of progress, Macao recently marked the significant milestone of its 25th anniversary since its return to the motherland. A special publication by an English-language newspaper highlighted various achievements that the region has made during this transformative period. Economic Growth and Transformation...

Continue Reading
Opportunity to Address Losses: Join Tempus AI Class Action

Updated Category News Views 128

Investors Encouraged to Participate in Tempus AI Class Action The law firm Robbins Geller Rudman & Dowd LLP is actively reaching out to investors of Tempus AI, Inc. (NASDAQ: TEM) who have experienced notable financial losses. They have announced an opportunity for eligible investors to take the lead in an associated class action lawsuit. This potential action stems from...

Continue Reading
Muncy Columbia Financial Corporation's Strong Q4 2024 Earnings

Updated Category News Views 99

Muncy Columbia Financial Corporation's Financial Outlook Muncy Columbia Financial Corporation (“Corporation”) (OTCQX: CCFN), after releasing its unaudited consolidated financial statements for the fourth quarter of 2024, has demonstrated significant improvement over the previous year. Fourth Quarter 2024 Financial Highlights For the quarter ending December 31, 2024,...

Continue Reading
Caris Life Sciences Expands Cancer Research Alliance

Updated Category News Views 119

Caris Life Sciences Expands Cancer Research Alliance Caris Life Sciences® (NASDAQ: CAI), a forefront player in precision medicine and next-generation AI TechBio, is excited to share the arrival of Providence Swedish Cancer Institute into the esteemed Caris Precision Oncology Alliance (Caris POA). This addition enhances their collective mission to revolutionize cancer...

Continue Reading
Zumiez Inc. Gears Up for First Quarter 2025 Financial Report

Updated Category News Views 263

Upcoming Financial Report for Zumiez Inc. Zumiez Inc. (NASDAQ: ZUMZ) has recently made an exciting announcement regarding its financial performance. The company is set to release its first quarter results for fiscal 2025 on June 5, after the stock market closes. This pivotal moment is eagerly anticipated by investors and stakeholders alike, as it will provide valuable...

Continue Reading